Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gentler IVF alternative tested for PCOS patients

NCT ID NCT07274202

Symptom relief Sponsor: Universitair Ziekenhuis Brussel Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares in vitro maturation (IVM) to conventional ovarian stimulation in 84 women with severe PCOS undergoing their first fertility treatment. The goal is to see which method causes less pain, fewer side effects, and better quality of life. Participants will fill out questionnaires at several points during treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
In vitro maturation (IVM) of oocytes
What this could lead to
If IVM works better, it could offer PCOS patients a gentler fertility treatment with fewer side effects and less pain.
What could go wrong
This is a small, early-stage trial (84 participants) measuring only patient-reported outcomes, not pregnancy success. IVM may not improve comfort or could have unknown drawbacks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age from \>18 to \<35 years * Patients with a PCOS diagnosis: The PCOS diagnosis will be based on the ESHRE PCOS guideline (2023) and the evidence-based methodology workshop on polycystic ovary syn-drome, December 3-5, 2012 using the following classification: Phenotype A (hyperandro-genism + oligo-/amenorrhea + PCOM), Phenotype C (hyperandrogenism + PCOM) and Phenotype D (oligo-/amenorrhea + PCOM). Hyperandrogenism is defined as the presence of clinical and/or biochemical hyperandrogenism following the ESHRE PCOS guideline, 2023. Oligomenorrhea or amenorrhea is considered as an average cycle duration \> 35 days. * A serum AMH concentration of \>10.00 ng/ml as measured using the Elecsys platform by Roche at UZ Brussel. Threshold of 10 ng/mL or higher was adopted based on the result of a multivariable analysis by our group (Mostinckx et al. (2024)), which showed that ongoing pregnancy rates in women with AMH of 10ng/mL or higher did not depend on the type of treatment (IVM vs. cOS). * Embarking on their first round of ART treatment at Brussels IVF. * Eligible for ART either because previous treatment with ovulation induction failed and/or because of male factor infertility. * Patients must be able to speak Dutch, French or English. Exclusion Criteria: * BMI \<18 or \>35 kg/m² * Patients with a general anesthesia during oocyte retrieval * Patients with a PCOS phenotype B will be excluded from the trial since these patients do not polycystic ovaries on ultrasound scan and are therefore not considered hyperrespond-ers. * Patients who do not have a partner * Need for preimplantation genetic testing (PGT) * high grade endometriosis (\> grade 2) * Couples who need donor oocytes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PCOS (polycystic ovary syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

polycystic ovary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PCOS (polycystic ovary syndrome)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.